nach oben

Rheumatology International

Erschienen in:

01.10.2011 | Original Article

Trichostatin A inhibits expression of cathepsins in experimental osteoarthritis

verfasst von: Wei-Ping Chen, Jia-Peng Bao, Jin-Li Tang, Peng-Fei Hu, Li-Dong Wu

Erschienen in: Rheumatology International | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the effects of trichostatin A (TSA) on expression of cathepsins in cartilage in experimental osteoarthritis (OA). OA was induced in 18 rabbits by bilateral anterior cruciate ligament transection (ACLT). Four weeks after surgery, rabbits received intra-articular injection with TSA dissolved in the dimethylsulphoxide (DMSO) in the right knees and DMSO in the left knees once a week for 5 weeks. Rabbits were killed 7 days after the last injection. The knee joints were assessed by morphological and histological examination. Messenger RNA expression of cathepsins K, B, L, S and cystatin C was studied by real-time PCR. TSA inhibited the expression of cathepsins K, B, L, S and cystatin C accompanied with the less degradation in cartilage. The results suggest that TSA exhibits protective effects against cartilage degradation in rabbits with OA and the effects may be associated with the inhibition of cathepsins.

Tortorella MD, Malfait AM, Deccico C, Arner E (2001) The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthr Cartil 9:539–552PubMedCrossRef

Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543PubMedCrossRef

Yasuda Y, Kaleta J, Bromme D (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973–993PubMedCrossRef

Dodds RA, Connor JR, Drake FH, Gowen M (1999) Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues. Arthritis Rheum 42:1588–1593PubMedCrossRef

Salminen-Mankonen HJ, Morko J, Vuorio E (2007) Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315–323PubMedCrossRef

Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ et al (2008) Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol 173:161–169PubMedCrossRef

Morko JP, Soderstrom M, Saamanen AM, Salminen HJ, Vuorio EI (2004) Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63:649–655PubMedCrossRef

Baici A, Lang A, Zwicky R, Muntener K (2005) Cathepsin B in osteoarthritis: uncontrolled proteolysis in the wrong place. Semin Arthritis Rheum 34(Suppl 2):24–28PubMed

Petanceska S, Canoll P, Devi LA (1996) Expression of rat cathepsin S in phagocytic cells. J Biol Chem 271:4403–4409PubMedCrossRef

10.

Nguyen Q, Mort JS, Roughley PJ (1990) Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. Biochem J 266:569–573PubMed

11.

Lang A, Horler D, Baici A (2000) The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol 27:1970–1979PubMed

12.

Martel-Pelletier J, Cloutier JM, Pelletier JP (1990) Cathepsin B and cysteine protease inhibitors in human osteoarthritis. J Orthop Res 8:336–344PubMedCrossRef

13.

Connor JR, Lepage C, Swift BA, Yamashita D, Bendele AM, Maul D et al (2009) Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthr Cartil 17:1236–1243PubMedCrossRef

14.

Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E et al (2009) Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 613:155–162PubMedCrossRef

15.

Piekarz R, Bates S (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289–2298PubMedCrossRef

16.

Chabane N, Zayed N, Afif H, Mfuna-Endam L, Benderdour M, Boileau C et al (2008) Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthr Cartil 16:1267–1274PubMedCrossRef

17.

Choi Y, Park SK, Kim HM, Kang JS, Yoon YD, Han SB et al (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp Mol Med 40:574–581PubMedCrossRef

18.

Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR et al (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7:R503–R512PubMedCrossRef

19.

Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N et al (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr Cartil 16:723–732PubMedCrossRef

20.

Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L et al (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150:862–872PubMedCrossRef

21.

Bao JP, Chen WP, Feng J, Zhao J, Shi ZL, Huang K et al (2009) Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: Regulation by dehydroepiandrosterone. Clin Chim Acta 408:1–7PubMedCrossRef

22.

Jo H, Ahn HJ, Kim EM, Kim HJ, Seong SC, Lee I et al (2004) Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. Arthritis Rheum 50:2531–2538PubMedCrossRef

23.

Shikhman AR, Amiel D, D’Lima D, Hwang SB, Hu C, Xu A et al (2005) Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis 64:89–94PubMedCrossRef

24.

Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA et al (2006) Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr Cartil 14:13–29PubMedCrossRef

25.

Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP (1998) Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 331:727–732PubMed

26.

Burleigh MC, Barrett AJ, Lazarus GS (1974) Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J 137:387–398PubMed

27.

Hou WS, Li Z, Buttner FH, Bartnik E, Bromme D (2003) Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 384:891–897PubMedCrossRef

28.

Kamolmatyakul S, Chen W, Yang S, Abe Y, Moroi R, Ashique AM et al (2004) IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway. J Dent Res 83:791–796PubMedCrossRef

29.

Ruettger A, Schueler S, Mollenhauer JA, Wiederanders B (2008) Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J Biol Chem 283:1043–1051PubMedCrossRef

30.

Kawaida R, Ohtsuka T, Okutsu J, Takahashi T, Kadono Y, Oda H et al (2003) Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med 197:1029–1035PubMedCrossRef

31.

Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL et al (2008) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 7:2139–2145PubMedCrossRef

32.

Zhong H, May MJ, Jimi E, Ghosh S (2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9:625–636PubMedCrossRef

33.

Kawamata N, Chen J, Koeffler HP (2007) Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110:2667–2673PubMedCrossRef

34.

Akasaki Y, Matsuda S, Nakayama K, Fukagawa S, Miura H, Iwamoto Y (2009) Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthr Cartil 17:235–243PubMedCrossRef

35.

Jean YH, Wen ZH, Chang YC, Hsieh SP, Lin JD, Tang CC et al (2008) Increase in excitatory amino acid concentration and transporters expression in osteoarthritic knees of anterior cruciate ligament transected rabbits. Osteoarthr Cartil 16:1442–1449PubMedCrossRef

Titel: Trichostatin A inhibits expression of cathepsins in experimental osteoarthritis
verfasst von: Wei-Ping Chen
Jia-Peng Bao
Jin-Li Tang
Peng-Fei Hu
Li-Dong Wu
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 10/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1481-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2011

A study on the efficacy of treatment with mud packs and baths with Sillene mineral water (Chianciano Spa Italy) in patients suffering from knee osteoarthritis

Regional migratory osteoporosis: case report of a patient with neuropathic pain

Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus

Echinococcus multilocularis infection and TNF inhibitor treatment in a patient with rheumatoid arthritis

The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients